The candidate vaccine’s next steps will be going through the FDA’s Biologics License Application process.
|Articles|January 24, 2008
Antihistamine's new label covers both indoor and outdoor allergies
In a new labeling change, Schering-Plough's Claritin can now treat both indoor and outdoor allergies
Advertisement
Schering-Plough reported that FDA has approved a labeling change for its over-the-counter Claritin (loratadine). The new label now states that the non-drowsy OTC drug relieves allergy symptoms caused by both indoor (or perennial) and outdoor (or seasonal) allergies. Indoor allergens include mold, dust mites, and pet dander, while outdoor allergens cover grass and pollen.
Advertisement
Related to this article
The Milken Institute released survey results alongside new data regarding the need for pharmacists in extending effective GLP-1 care.
Through the ACCESS program, Mark Ey, RPh, notes that pharmacies can now start billing for a variety of services they’ve already been providing.
The medication significantly increased risk of pregnancy loss when compared with macrolide antibiotics, amoxicillin, and topical clindamycin for acne.
In part 3, Rebold explores improving the ART formulary protocol through introducing pharmacist-led transition-of-care services.
Our hosts explore why ketone monitoring matters, what pharmacists should know about Libre Duo, and how patient education can support proactive care management.
Mark Ey, RPh, details the patient-focused factors of the ACCESS to Pharmacy Care Program and the ways in which valued care translates to reimbursement.
A new option for adults who have experienced stroke will now be available to further reduce future risk.
Advertisement
Advertisement
Trending on Drug Topics
1
FDA Adds NAION Eye Risk Warning to All GLP-1 Labels
2
The Pharmacy Model Creating New Billing Pathways, Improved Recognition
3
Doxycycline Use Associated with Higher Risk of Pregnancy Loss
4
Wicked Good Cardiometabolic Chat: Ketone Monitoring in Pharmacy Practice
5